Today s Dietitian magazine, the leading news source for dietitians and nutritionists, covering topics such as diabetes management, long-term care, new products and technologies, career strategies, nutrition research updates, supplements, culinary arts, food allergies, fitness, sports medicine, and much more.
The database shows 4,730 scholars have an h-index above 100. The h-index is a gauge of productivity and the impact of published papers. The index takes into account the researcher’s total number of papers and how many times each was cited by other scholars.
These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits, said Steve Heymsfield, MD, FTOS, past president of
The Obesity Society and corresponding author of the study. Heymsfield is professor and director of the Metabolism and Body Composition Laboratory at the Pennington Biomedical Research Center in Baton Rouge, La.
What Is Bimagrumab?
The study describes bimagrumab (BYM338; Novartis) as a human monoclonal antibody that binds to activin Type II receptors (ActRII) and in turn prevents specific molecular components from inhibiting skeletal muscle growth. Earlier studies involving skeletal muscle in mice, found that bimagrumab treatment had an effect on brown adipose tissue (BAT) differentiation and activity.
Drug found to be safe and effective for treating patients with obesity and type 2 diabetes
A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.
These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits.
Steve Heymsfield, MD, FTOS, Past President of The Obesity Society and Corresponding Author of the Study
E-Mail
SILVER SPRING, Md. A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. These exciting results suggest that there may be a novel mechanism for achieving weight loss with a profound loss of body fat and an increase in lean mass, along with other metabolic benefits, said Steve Heymsfield, MD, FTOS, past president of The Obesity Society and corresponding author of the study. Heymsfield is professor and director of the Metabolism and Body Composition Laboratory at the Pennington Biomedical Research Center in Baton Rouge, La.